Notably, the combination of BI-D1870 with the BCL2 inhibitor venetoclax exhibited high activity against cells of MCL cell lines, which responded only moderately to venetoclax monotherapy. The gene discussed is CACNA1A; the disease is mantle cell lymphoma.